ABSTRACT
INTRODUCCIÓN: La enfermedad de Alzheimer (EA) es una patología neurodegenerativa caracterizada por demencia de carácter progresivo asociada a una perdida global de funciones cognitivas. MÉTODOS: Se realizó una síntesis de evidencia a través de una revisión sistemática con metaanálisis de ensayos clínicos que hayan evaluado la suplementación de omega-3 en pacientes con EA. OBJETIVO: Determinar si existe evidencia científica que avale la efectividad de la suplementación omega-3 en la mejoría de la función cognitiva de pacientes con EA. Estrategia de búsqueda: La estrategia de búsqueda incluyó solo ensayos clínicos aleatorizados (ECA). Las bases de datos usadas fueron: Medline, Cochrane Central, Cinahl y Lilacs. Además, se realizó una búsqueda electrónica en Google Scholar. Selección de estudios: Se obtuvieron 6 artículos que cumplían con nuestros criterios de elegibilidad. Se evaluó el riesgo de sesgo según el método Cochrane. CONCLUSIÓN: No hay evidencia consistente que avale la suplementación de omega-3 versus placebo en la mejoría de la función cognitiva de pacientes con EA a corto y mediano plazo
INTRODUCTION: Alzheimer disease (AD) is a neurodegenerative disease characterised by progressive dementia associated with global cognitive dysfunction. METHODS: We conducted a systematic review and meta-analysis of clinical trials evaluating omega-3 supplementation in patients with AD. OBJECTIVE: To determine if there is scientific evidence of the effectiveness of omega-3 supplementation in improving cognitive function in patients with AD. Search strategy: We included only randomised controlled trials (RCTs) from the following databases: Medline, Cochrane Central, Cinahl, and LILACS. An electronic search was also conducted using Google Scholar. Study selection: Six articles met the eligibility criteria. The risk of bias was assessed following the Cochrane method. CONCLUSION: There is no consistent evidence to support the effectiveness of omega-3 supplementation in improving cognitive function in AD patients in the short and medium term
Subject(s)
Humans , Alzheimer Disease/drug therapy , Cognitive Dysfunction/drug therapy , Dietary Supplements , Fatty Acids, Omega-3/administration & dosage , Randomized Controlled Trials as TopicABSTRACT
INTRODUCTION: Alzheimer disease (AD) is a neurodegenerative disease characterised by progressive dementia associated with global cognitive dysfunction. METHODS: We conducted a systematic review and meta-analysis of clinical trials evaluating omega-3 supplementation in patients with AD. OBJECTIVE: To determine if there is scientific evidence of the effectiveness of omega-3 supplementation in improving cognitive function in patients with AD. SEARCH STRATEGY: We included only randomised controlled trials (RCTs) from the following databases: Medline, Cochrane Central, Cinahl, and LILACS. An electronic search was also conducted using Google Scholar. STUDY SELECTION: Six articles met the eligibility criteria. The risk of bias was assessed following the Cochrane method. CONCLUSION: There is no consistent evidence to support the effectiveness of omega-3 supplementation in improving cognitive function in AD patients in the short and medium term.
